Related Experiment Video
Updated: Jul 8, 2026

09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Secondary B-Cell Acute Lymphoblastic Leukemia Following Multiple Myeloma Treatment
Clinical Laboratory
|July 7, 2026
Summary
Secondary B-cell acute lymphoblastic leukemia (B-ALL) is a rare complication after multiple myeloma (MM) treatment. Bortezomib therapy and autologous stem cell transplant for MM may increase the risk of developing secondary B-ALL.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Secondary B-cell acute lymphoblastic leukemia (B-ALL) following multiple myeloma (MM) is a rare clinical occurrence.
- Understanding the risk factors and potential links between MM treatments and secondary malignancies is crucial for patient care.